Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response

查看全文 作　　者：Jingjing [1,2]He;Xinxin [1,2]Xiong;Han [1]Yang;Dandan [1]Li;Xuefei [1]Liu;Shuo [1]Li;Shuangye [1]Liao;Siyu [3]Chen;Xizhi [1]Wen;Kuai [1]Yu;Lingyi [1]Fu;Xingjun [1]Dong;Kaiyu [1]Zhu;Xiaojun [1]Xia;Tiebang [1]Kang;Chaochao [4]Bian;Xiang [4]Li;Haiping [4]Liu;Peirong [1]Ding;Xiaoshi [1]Zhang;Zhenjiang [1]Liu;Wende [3]Li;Zhixiang [1]Zuo;Penghui [1]Zhou

机构地区：[1]State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou,China;[2]Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;[3]Guangdong Laboratory Animals Monitoring Institute,Guangdong Key Laboratory of Laboratory Animals,Guangzhou,China;[4]Guangzhou FineImmune Biotechnology Co.,LTD,Guangzhou,China

出　　处：《Cell Research》索引2022年第32卷第6期,共13页

基　　金：supported by grants from the National Key R&D Program of China(2016YFA0500304);the National Nature Science Foundation of China(NSFC)(81773052,81572806,81802854,81802853);the Guangzhou Science Technology and Innovation Commission(201607020038);the Natural Science Foundation of Guangdong Province(2017A030308007);the Guangdong Innovative and Entrepreneurial Research Team Program(2016ZT06S638);the Leading Talents Program of Guangdong Province(2016LJ06S464). 摘　　要：Personalized immunotherapy targeting tumor-specific antigens(TSAs)could generate efficient and safe antitumor immune response without damaging normal tissues.Although neoantigen vaccines have shown therapeutic effect in clinic trials,precise prediction of neoantigens from tumor mutations is still challenging.The host antitumor immune response selects and activates T cells recognizing tumor antigens.Hence,T cells engineered with T-cell receptors(TCRs)from these naturally occurring tumor antigen-specific T(Tas)cells in a patient will target personal TSAs in his/her tumor.To establish such a personalized TCR-T cell therapy,we comprehensively characterized T cells in tumor and its adjacent tissues by single-cell mRNA sequencing(scRNA-seq),TCR sequencing(TCR-seq)and in vitro neoantigen stimulation.Compared to bystander T cells circulating among tissues,Tas cells were characterized by tumor enrichment,tumor-specific clonal expansion and neoantigen specificity.We found that CXCL13 is a unique marker for both CD4^(+)and CD8^(+)Tas cells.Importantly,TCR-T cells expressing TCRs from Tas cells showed significant therapeutic effects on autologous patient-derived xenograft(PDX)tumors.Intratumoral Tas cell levels measured by CXCL13 expression precisely predicted the response to immune checkpoint blockade,indicating a critical role of Tas cells in the antitumor immunity.We further identified CD200 and ENTPD1 as surface markers for CD4^(^(+))and CD8^(^(+))Tas cells respectively,which enabled the isolation of Tas cells from tumor by Fluorescence Activating Cell Sorter(FACS)sorting.Overall,our results suggest that TCR-T cells engineered with Tas TCRs are a promising agent for personalized immunotherapy,and intratumoral Tas cell levels determine the response to immunotherapy. 关键词：IMMUNOTHERAPY SPECIFICITY TCR

相关文献

参考文献（40）
引证文献（27）
耦合文献（2）

参考文献(40)

引证文献(27)

耦合文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response

参考文献(40)

引证文献(27)

耦合文献(2)

用户提示